A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
